Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BPZE1 vaccine in healthy adults
NCT03541499Phase 2Completed
- Sponsor
- National Institute of Allergy and Infectious Diseases
- Start
- Oct 2018
- Primary completion
- May 2020
- Modality
- Live Biotherapeutic Products, Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, single-blind trial of BPZE1 in pertussis (4 arms), sponsored by National Institute of Allergy and Infectious Diseases. Primary endpoints: Adverse Events of Special Interest, Serious Adverse Events and 2 more. Started Oct 2018; status: completed.
02
Drugs
BPZE1
03
Conditions
pertussis
Beyond the preview
Go deeper on NCT03541499.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03541499.